These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 4563493

  • 1. Parkinson's disease. Modification by 5-hydroxytryptophan.
    Chase TN, Ng LK, Watanabe AM.
    Neurology; 1972 May; 22(5):479-84. PubMed ID: 4563493
    [No Abstract] [Full Text] [Related]

  • 2. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK, Sonninen V, Siirtola T.
    Eur Neurol; 1973 May; 9(6):349-62. PubMed ID: 4712542
    [No Abstract] [Full Text] [Related]

  • 3. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
    Chase TN, Watanabe AM.
    Neurology; 1972 Apr; 22(4):384-92. PubMed ID: 5062828
    [No Abstract] [Full Text] [Related]

  • 4. Central monoamine metabolism in Parkinson's disease.
    Chase TN, Ng LK.
    Arch Neurol; 1972 Dec; 27(6):486-91. PubMed ID: 5083866
    [No Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN.
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract] [Full Text] [Related]

  • 6. Behavioral changes of chronic schizophrenic patients given L-5-hydroxytryptophan.
    Wyatt RJ, Vaughan T, Galanter M, Kaplan J, Green R.
    Science; 1972 Sep 22; 177(4054):1124-6. PubMed ID: 4560057
    [Abstract] [Full Text] [Related]

  • 7. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J, Sharpe D, Curzon G.
    J Neurol Sci; 1973 May 22; 19(1):1-12. PubMed ID: 4715017
    [No Abstract] [Full Text] [Related]

  • 8. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H.
    Arch Neurol; 1973 Feb 22; 28(2):91-5. PubMed ID: 4683155
    [No Abstract] [Full Text] [Related]

  • 9. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH, Bowers MB.
    Experientia; 1970 Feb 22; 26(2):161-3. PubMed ID: 5308739
    [No Abstract] [Full Text] [Related]

  • 10. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B, Roos BE.
    Eur J Clin Pharmacol; 1971 Sep 22; 3(4):232-5. PubMed ID: 5151306
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, Bartholini G, Constantinidis J, Eisenring JJ, Geissbühler F, Yanniotis G, de Ajuriaguerra J.
    Schweiz Med Wochenschr; 1973 Oct 20; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract] [Full Text] [Related]

  • 12. Serotonergic mechanisms and extrapyramidal function in man.
    Chase TN.
    Adv Neurol; 1974 Oct 20; 5():31-9. PubMed ID: 4280243
    [No Abstract] [Full Text] [Related]

  • 13. Serotonergic mechanisms in Parkinson's disease.
    Chase TN.
    Arch Neurol; 1972 Oct 20; 27(4):354-6. PubMed ID: 4262400
    [No Abstract] [Full Text] [Related]

  • 14. The balance of biogenic amines as condition for normal behaviour.
    Birkmayer W, Danielczyk W, Neumayer E, Riederer P.
    J Neural Transm; 1972 Oct 20; 33(2):163-78. PubMed ID: 4643007
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.
    Rinne UK, Sonninen V, Sirtola T.
    Z Neurol; 1972 Oct 20; 202(1):1-20. PubMed ID: 4114458
    [No Abstract] [Full Text] [Related]

  • 16. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ, Somerville B.
    Med J Aust; 1974 Mar 23; 1(12):429-32. PubMed ID: 4598384
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK, Sonninen V, Siirtola T.
    Eur Neurol; 1972 Mar 23; 7(4):228-40. PubMed ID: 4556618
    [No Abstract] [Full Text] [Related]

  • 18. Levodopa: alterations in behavior.
    Goodwin FK, Murphy DL, Brodie HK, Bunney WE.
    Clin Pharmacol Ther; 1971 Mar 23; 12(2):383-96. PubMed ID: 4930867
    [No Abstract] [Full Text] [Related]

  • 19. Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.
    Goodwin FK, Brodie HK, Murphy DL, Bunney WE.
    Lancet; 1970 May 02; 1(7653):908-11. PubMed ID: 4191547
    [No Abstract] [Full Text] [Related]

  • 20. Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase.
    Reid JL, Calne DB, Vakil SD, Allen JG, Davies CA.
    J Neurol Sci; 1972 Sep 02; 17(1):45-51. PubMed ID: 4560435
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.